Tandem pump, paired with Dexcom CGM, boosts blood glucose control in Type 2 diabetics – MedTech Dive

In preparation for an attempt to expand into the Type 2 market, Tandem sponsored a clinical trial that evaluated the effect of switching patients from multiple daily injections or basal insulin only to its t:slim X2 insulin pump with Control-IQ technology. Control-IQ automatically adjusts basal insulin based on data from a compatible integrated continuous glucose monitor.
After tracking patients on their original regimens for two to four weeks, the investigators gave all the participants the Tandem technology and a Dexcom G6 continuous glucose monitor. The study tracked the effects of the Tandem technology over six weeks. 
Over that period, mean time in the 70 to 180 mg/dL target range improved by 15 percentage points, the study found. The change reflected similar improvements in both patients who previously took multiple daily injections and prior basal insulin only. Tandem saw no increase in CGM-measured hypoglycemia. Median time in closed loop was 96% and participants indicated a high level of satisfaction with the system.
“The combination of safety outcomes and high satisfaction scores seen in this population, who were able to continue these existing medications during the study, shows that Control-IQ technology could be a powerful management solution for their therapy needs,” Jordan Pinsker, vice president and medical director for Tandem, said in a statement.
Get the free daily newsletter read by industry experts
Commercial laboratories and academic medical centers are starting to adopt digital tools to help pathologists detect cancer, opening a large market for AI-powered diagnostic tools.
Analysts at Rock Health said “the market isn’t the same as it was” after seeing a sharp drop in late-stage deals.
Subscribe to MedTech Dive for top news, trends & analysis
Get the free daily newsletter read by industry experts
Commercial laboratories and academic medical centers are starting to adopt digital tools to help pathologists detect cancer, opening a large market for AI-powered diagnostic tools.
Analysts at Rock Health said “the market isn’t the same as it was” after seeing a sharp drop in late-stage deals.
The free newsletter covering the top industry headlines

source